is a medical plan provider that allows members to have real-time webcam & telephone consultation with our doctors anytime, anywhere. Doctor Online Consultation's medical consultation services are done real-time via webcam or telephone through our advanced medical portal and telephony technology to connect our members to our doctors instantly.
Saturday, September 26, 2015
Availability of Medical Abortion in the U.S. Continues to Provide Women Safe Alternative, 15-Years after FDA Approval
WASHINGTON--(BUSINESS WIRE)--This September marks the 15-year anniversary of the U.S. Buy Aldara (Imiquimod) with free prescription Food and Drug
Administration (FDA) s approval of the use of Mifepristone
(also known as RU-486 or the "abortion pill"). About Zantac (Ranitidine) without prescription Mifepristone is the first
and only FDA approved medication to provide women with a safe and
effective non-surgical option to end an early pregnancy.
“Medication abortion is an empowering, private, and non-invasive
procedure that puts the control back in the woman’s hands. About Super Active Pack-40 () without prescription Carafem is
proud to focus on the availability of the abortion pill along with a
variety of birth control options to provide women choices and support
their decisions regarding the timing and spacing of their children,”
says Melissa Grant VP of Carafem. Buy Flutex
“Women are given Mifepristone in our health center, to be followed by
another medication called Misoprostol, usually taken at home the same
day or up to 72 hours later. Inderal La (Propranolol) with no prescription Having options for how and when to use
these medications allows a woman more flexibility and control around
when and where she experiences the abortion process. Buy CoQ10 Supplements online Medication abortion
does not require surgery or anesthesia.”
The proportion of women in the United States deciding to end a pregnancy
by medication has been steadily growing since Mifepristone’s approval. http://doctor-answers.blogspot.com/
Since 2000, more than 2 million women in the United States have chosen
medication abortion for ending an early pregnancy. There is overwhelming
evidence that medication abortion is safe for virtually all women.
Never before has abortion been safer, less invasive and more affordable
than with medication abortion and Carafem focuses on the provision of
this method for early abortion care. By providing same-day appointments,
one-on-one private visits with a knowledgeable clinician, financial
assistance, and visits that routinely last no more than an hour, Carafem
is responding to a critical need in women’s reproductive healthcare.
Medically unnecessary restrictions have contributed to the abortion pill
not being as widely available to women as it could be. The reality is
that these regulations do nothing to make abortion safer- but they make
it more costly and less available.
“Carafem is proud to ensure that women are aware of all of their
reproductive health care options through education in our health centers
and through our honest and cutting-edge advertising campaigns. Carafem
aims to lift the stigma that surrounds this common medical procedure,”
adds Grant.
On the 15th anniversary of Mifepristone’s approval in the
U.S., Carafem
aims to deflate negativity and increase awareness of something that is,
and has been, common in our society. In fact, 1 in 3 women will choose
to have an abortion during her reproductive lifetime. This statistic
offers cultural validation for updating the conversation and highlights
the importance of access to quality health care.
Friday, September 11, 2015
Biogen Prices $6.0 Billion of Senior Unsecured Notes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the pricing of four series
of senior unsecured notes for an aggregate principal amount of $6.0
billion. Buy Zofran (Ondansetron) without prescription The notes will mature as follows:
$1.50 billion will mature on September 15, 2020 and will bear interest
at an annual rate of 2.900%
$1.00 billion will mature on September 15, 2022 and will bear interest
at an annual rate of 3.625%
$1.75 billion will mature on September 15, 2025 and will bear interest
at an annual rate of 4.050%
$1.75 billion will mature on September 15, 2045 and will bear interest
at an annual rate of 5.200%
The offering is expected to close on September 15, 2015, subject to
customary closing conditions.
Biogen intends to use the net proceeds from this offering, together with
cash on hand, to fund share repurchases of its common stock under the
company’s previously authorized $5.0 billion share repurchase program,
for working capital and other general corporate purposes.
Goldman, Sachs & Co. Azulfidine (Sulfasalazine) with no prescription and Merrill Lynch, Pierce, Fenner & Smith
Incorporated are acting as joint book-running managers and
representatives of the several underwriters. Avapro (Irbesartan) with free Rx A copy of the preliminary
prospectus supplement and the accompanying base prospectus, which is
filed as part of Biogen’s effective shelf registration statement on Form
S-3 filed on September 8, 2015 (File No. About Felogard without prescription 333-206799), may be obtained
from either of the representatives by calling Goldman, Sachs & Co. About Maxalt (Rizatriptan)
toll-free at 1 (866) 471-2526 or Merrill Lynch, Pierce, Fenner & Smith
Incorporated toll-free at 1 (800) 294-1322.
An electronic copy of the prospectus supplement and the accompanying
base prospectus may also be obtained at no charge at the Securities and
Exchange Commission’s website at .sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be any
sale of securities in any state or other jurisdiction where such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction, where the offer, solicitation or sale of these securities
would be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction. Buy Cat’s Claw online The offering of
the notes may be made only by means of a prospectus supplement and the
accompanying base prospectus.
About BiogenThrough cutting-edge science and medicine,
Biogen discovers, develops and delivers to patients worldwide innovative
therapies for the treatment of neurodegenerative diseases, hematologic
conditions and autoimmune disorders. http://future-pharmaceuticals.blogspot.com Founded in 1978, Biogen is one of
the world’s oldest independent biotechnology companies and patients
worldwide benefit from its leading multiple sclerosis and innovative
hemophilia therapies.
Biogen Safe Harbor StatementThis press release contains
forward-looking statements that involve risks and uncertainties,
including statements about the expected use of proceeds and timing of
completion of the offering. You should not place undue reliance on these
statements. These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in such
statements. The offering may also be adversely affected by market
conditions, adverse changes to Biogen’s business or prospects, and the
other risks and uncertainties that are described in Biogen’s filings
with the Securities and Exchange Commission. These statements are based
on current beliefs and expectations and speak only as of the date of
this press release. Biogen does not undertake any obligation to publicly
update any forward-looking statements.
Wednesday, September 2, 2015
Eosinophilic Esophagitis Pipeline Review, H2 2015 - 7 Companies & 8 Drug Profiles
. About Etoricoxib with free prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/bgmx8f/eosinophilic)
has announced the addition of the "Eosinophilic
Esophagitis - Pipeline Review, H2 2015" report to their
offering.
This report provides comprehensive information on the therapeutic
development for Eosinophilic Esophagitis, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases. About Noroxin (Norfloxacin) Buy Vermox (Mebendazole) with free Rx
It also reviews key players involved in the therapeutic development for
Eosinophilic Esophagitis and special features on late-stage and
discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. Buy Breast Enhancement online Buy Cialis Daily (Tadalafil) with free prescription It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
Allergan Plc
DBV Technologies S.A.
Dr. http://medical-questions-answers.blogspot.com Buy Indocin (Indomethacin) Falk Pharma GmbH
Novartis AG
Receptos, Inc.
Regeneron Pharmaceuticals, Inc.
Shire Plc
Drug Profiles
Allergen for Milk Allergy
budesonide
budesonide
dectrekumab
dupilumab
EUR-1100
Qi-406
RPC-4046
For more information visit .researchandmarkets.com/research/bgmx8f/eosinophilic
Subscribe to:
Posts (Atom)